FIELD: medicine.
SUBSTANCE: present invention refers to medicine, namely to a method for detecting patients with progressing leukaemia and/or lymphoma and a risk of developing side effects of administering the CD19×CD3 bispecific antibody. A B:T cell ratio is measured in the patients; the ratio of 1:9 or less indicates the risk of possible side effects in the above patient. A dose schedule of the CD19×CD3 bispecific antibody provides: (a) administering the first dose of the CD19×CD3 bispecific antibody for the first time period; and then (b) administering the second dose of the above antibody for the second time period; the above second dose exceeds the above first dose.
EFFECT: using the given method enables facilitating the clinical course or preventing any side effect caused by administering the above bispecific antibody when treating the patients with leukaemia and/or lymphoma.
34 cl, 2 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW TREATMENT OF THE ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN | 2014 |
|
RU2677324C2 |
| NEW TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN | 2018 |
|
RU2736802C2 |
| NEW TREATMENT OF ACUTE LYMPHOBLASTIC LEUKAEMIA IN CHILDREN | 2009 |
|
RU2536933C2 |
| NEW TREATMENT OF ACUTE LYMPHOBLASTIC LEUKAEMIA | 2009 |
|
RU2536940C2 |
| BISPECIFIC ANTIBODIES AGAINST CD3*CD19 | 2015 |
|
RU2651776C2 |
| ANTI-CD3*CD19 FLEXIBODY-BASED PHARMACEUTICAL COMPOSITIONS FOR TREATING B-CELL DISEASES | 2014 |
|
RU2568910C2 |
| DOSING REGIMEN FOR A HYBRID PROTEIN GP100-SPECIFIC REDIRECTING TCR-ANTI-CD3 SCFV | 2017 |
|
RU2766119C2 |
| CD19 X CD3-SPECIFIC POLYPEPTIDES AND THEIR APPLICATION | 1999 |
|
RU2228202C2 |
| COMBINATION THERAPY FOR STABLE AND LONG-TERM TRANSPLANT ENGRAFTMENT | 2012 |
|
RU2657758C2 |
| COMBINATION THERAPY FOR STABLE AND LONG TERM ENGRAFTMENT USING SPECIFIC PROTOCOLS FOR T/B-CELL DEPLETION | 2012 |
|
RU2648354C2 |
